Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
2.
J Med Chem ; 55(5): 2388-405, 2012 Mar 08.
Artigo em Inglês | MEDLINE | ID: mdl-22364337

RESUMO

The discovery and characterization of compound 48, a selective and in vivo active mGlu2 receptor positive allosteric modulator (PAM), are described. A key to the discovery was the rational exploration of the initial HTS hit 13 guided by an overlay model built with reported mGlu2 receptor PAM chemotypes. The initial weak in vitro activity of the hit 13 was quickly improved, although compounds still had suboptimal druglike properties. Subsequent modulation of the physicochemical properties resulted in compounds having a more balanced profile, combining good potency and in vivo pharmacokinetic properties. Final refinement by addressing cardiovascular safety liabilities led to the discovery of compound 48. Besides good potency, selectivity, and ADME properties, compound 48 displayed robust in vivo activity in a sleep-wake electroencephalogram (sw-EEG) assay consistent with mGlu2 receptor activation, in accordance with previous work from our laboratories.


Assuntos
Nitrilas/síntese química , Piridonas/síntese química , Receptores de Glutamato Metabotrópico/agonistas , Regulação Alostérica , Animais , Encéfalo/metabolismo , Sinergismo Farmacológico , Canal de Potássio ERG1 , Eletroencefalografia , Canais de Potássio Éter-A-Go-Go/fisiologia , Células HEK293 , Humanos , Isomerismo , Camundongos , Nitrilas/farmacocinética , Nitrilas/farmacologia , Técnicas de Patch-Clamp , Piridonas/farmacocinética , Piridonas/farmacologia , Ratos , Receptores de Glutamato Metabotrópico/metabolismo , Sono REM/efeitos dos fármacos , Relação Estrutura-Atividade , Vigília
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa